Industry: Pharmaceuticals, Biotechnology
Omeros is developing its chondroprotective technology based on a systems biology approach to address osteoarthritis, rheumatoid arthritis and other disorders that are associated with inflammation-induced cartilage loss. Omeros’ chondroprotective product candidates combine a therapeutic agent selected to inhibit cartilage degradation with an agent expected to promote the formation of healthy cartilage. These agents are intended to work in concert to prevent additional cartilage damage and rebuild lost cartilage matrix. Omeros believes that this combination approach may provide therapeutic improvement over any single degradation inhibitor or growth promoter, leading to an important new treatment option for cartilage ( www.omeros.com )
Omeros Corporation
1420 Fifth Avenue Suite 2600
Seattle, Washington 98101
USA
Tel: (206) 676-5000
Fax: (206) 264-7856